News for Galapagos NV (GXE.F)

CALGARY, AB, March 5, 2021 /CNW/ - Avanti Software, a leader in Canadian People Management solutions has made it to the 2021 list of Top 50 Great Places to Work® in CanadaSince 2018, Avanti Software has been consistently designated Great Place to Work® Certified and has been listed as a top Alberta employer, as well as a Best Workplace for Millennials and Youth, and Technology. This is the organization's first time on Top 50 Great Places to Work® in Canada list.

Guru adds to health care holdings with biotech focused on cancer, serious diseases

Steven Cohen Dives Into Chimerix, Stocks: CMRX,ALNY,DRNA,MRTX,GLPG,CRIS,AGLE,ATRA,BLU,BDTX, Steven Cohen, release date:Feb 24, 2021

Steven Cohen Dives Into Chimerix, Stocks: CMRX,ALNY,DRNA,MRTX,GLPG,CRIS,AGLE,ATRA,BLU,BDTX, Steven Cohen, release date:Feb 24, 2021

Sands Capital Trims Microsoft, Exits Regeneron Pharmaceuticals, Stocks: MSFT,REGN,SNOW,SE,GLPG,MNST, Frank Sands, release date:Feb 23, 2021

Sands Capital Trims Microsoft, Exits Regeneron Pharmaceuticals, Stocks: MSFT,REGN,SNOW,SE,GLPG,MNST, Frank Sands, release date:Feb 23, 2021

NEW YORK, NY / ACCESSWIRE / February 20, 2021 / Pomerantz LLP is investigating claims on behalf of investors of Galapagos NV ("Galapagos" or the "Company") (NASDAQ:GLPG). Such investors are advised to contact Robert S.

NEW YORK, Feb. 19, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of?Galapagos NV??.? Such investors are advised to contact Robert S.... | February 19, 2021

NEW YORK, Feb. 19, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Galapagos NV ("Galapagos" or the "Company") (NASDAQ:

Today's Daily Dose brings you news about Bio-Path's patented DNAbilize platform technology, Cancer Genetics' stock offering, Galapagos/Gilead scrapping Ziritaxestat and FDA approving the expanded approval of Regeneron's Libtayo.

Galapagos NV (NASDAQ:GLPG) has lost ~15.3% in value so far today after the Belgium biotech and Gilead Sciences (GILD +0.8%) announced their decision to halt the ISABELA Phase 3 clinical...

NOT FOR DISTRIBUTION IN THE UNITED KINGDOM   NICE guidance, for the first time in the UK, supports access to an advanced therapy for people with moderate ...